Literature DB >> 8467174

Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC.

S Ono1, S Tamakuma, H Mochizuki, M Kinoshita, Y Ohkusa, S Aosasa, Y Oda, H Ohe.   

Abstract

Various toxic factors induced by endotoxin (Et) are thought to be deeply involved in the pathogenesis of severe infections. In this study, particular attention was paid to the role of the platelet-activating factor (PAF) in these conditions, and clinical and experimental studies were conducted on the relationship between PAF and the changes observed in the general parameters after surgical infections. In the clinical study, changes in the PAF concentration in the blood of seven patients with disseminated intravascular coagulation (DIC), five of whom were septic and two non-septic, were monitored by gas/mas spectrometry. The mean PAF level in the septic DIC group tended to be higher than that in the non-septic DIC group. Moreover, in the septic DIC group, the relationship between the increase in the PAF level and platelet count was analyzed with the lapse of time and we surmised a negative correlation between these parameters. Experimentally, we also investigated the role of PAF in Et shock and the effect of an anti-PAF agent and protease inhibitor. The Et-induced fall in blood pressure was similarly prevented by both the anti-PAF agent and protease inhibitor. However, the decrease in the platelet count was more significantly inhibited by the anti-PAF agent than by the protease inhibitor, whereas the parameters of the blood coagulation/fibrinolysis system were more affected by the protease inhibitor than by the anti-PAF agent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467174     DOI: 10.1007/bf00309232

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  6 in total

1.  [Clinico-experimental analysis of backgrounds of the severe surgical infections].

Authors:  S Ono; S Tamakuma; H Mochizuki; T Kadota; T Yamamoto
Journal:  Nihon Geka Gakkai Zasshi       Date:  1991-09

2.  Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.

Authors:  Z Terashita; Y Imura; K Nishikawa
Journal:  Biochem Pharmacol       Date:  1985-05-01       Impact factor: 5.858

3.  Direct evidence of elevated levels of circulating platelet-activating factor in a patient with disseminated intravascular coagulation syndrome.

Authors:  K Sakaguchi; F Masugi; Y H Chen; M Inoue; T Ogihara; K Yamada; I Yamatsu
Journal:  J Lipid Mediat       Date:  1989 May-Jun

4.  Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.

Authors:  Y Imura; Z Terashita; K Nishikawa
Journal:  Life Sci       Date:  1986-07-14       Impact factor: 5.037

5.  Highly sensitive gas chromatographic--mass spectrometric method for the determination of platelet-activating factor in human blood.

Authors:  K Yamada; O Asano; T Yoshimura; K Katayama
Journal:  J Chromatogr       Date:  1988-12-09

Review 6.  Platelet-activating factor and cytokine interactions in shock.

Authors:  D Hosford; M Paubert-Braquet; P Braquet
Journal:  Resuscitation       Date:  1989-12       Impact factor: 5.262

  6 in total
  2 in total

1.  Involvement of platelet activation in experimental osteonecrosis in rabbits.

Authors:  K Masuhara; K Nakata; S Yamasaki; H Miki; H Yoshikawa
Journal:  Int J Exp Pathol       Date:  2001-10       Impact factor: 1.925

2.  Platelet-activating factor (PAF) and the development of chronic subdural haematoma.

Authors:  Y Hirasima; S Endo; R Kato; T Ohmori; T Nagahori; M Nishijima; K Karasawa; S Nojima; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.